Center Publications

Anderson, Lindsey J, et al. “Evaluation of Physical Function and Its Association With Body Composition, Quality of Life and Biomarkers in Cancer Cachexia Patients”. 2021. Clinical Nutrition (Edinburgh, Scotland), vol. 40, no. 3, 2021, pp. 978–986.

Hsu, Liana, et al. “Fast-Acting Insulin Aspart Use With the MiniMed 670G System”. 2021. Diabetes Technology & Therapeutics, vol. 23, no. 1, 2021, pp. 1–7.

Stone, Stephen I, et al. “Monogenic and Syndromic Diabetes Due to Endoplasmic Reticulum Stress”. 2021. Journal of Diabetes and Its Complications, vol. 35, no. 1, 2021, p. 107618.

Hockett, Christine W, et al. “Clinical Profile at Diagnosis With Youth-Onset Type 1 and Type 2 Diabetes in Two Pediatric Diabetes Registries: SEARCH (United States) and YDR (India)”. 2021. Pediatric Diabetes, vol. 22, no. 1, 2021, pp. 22–30.

Bennett, Hunter, et al. “Epigenetic Regulation of Kupffer Cell Function in Health and Disease”. 2020. Frontiers in Immunology, vol. 11, 2020, p. 609618.

Mitchell, Angela M, and Aaron W Michels. “T Cell Receptor Sequencing in Autoimmunity”. 2020. Journal of Life Sciences (Westlake Village, Calif.), vol. 2, no. 4, 2020, pp. 38–58.

Iqbal, Niloy Jafar, et al. “Cyclin-Dependent Kinase 4 6 Inhibitors Require an Arcuate to Paraventricular Hypothalamus Melanocortin Circuit to Treat Diet-Induced Obesity”. 2020. American Journal of Physiology. Endocrinology and Metabolism, 2020.

Puppione, Don L, et al. “Naked Mole-Rat, a Rodent With an Apolipoprotein A-I Dimer”. 2020. Lipids, 2020.

Liu, Jianyun, et al. “Sex Discrepancy in the Reduction of Mucosal-Associated Invariant T Cells Caused by Obesity”. 2020. Immunity, Inflammation and Disease, 2020.

Harris, Tatiyana, et al. “DLK1 Expressed in Mouse Orexin Neurons Modulates Anxio-Depressive Behavior But Not Energy Balance”. 2020. Brain Sciences, vol. 10, no. 12, 2020.

Deem, Jennifer, et al. “Cold-Induced Hyperphagia Requires AgRP-Neuron Activation in Mice”. 2020. ELife, vol. 9, 2020.

Buse, John B, et al. “Long-Term Efficacy and Safety of Oral Semaglutide and the Effect of Switching from Sitagliptin to Oral Semaglutide in Patients With Type 2 Diabetes: A 52-Week, Randomized, Open-Label Extension of the PIONEER 7 Trial”. 2020. BMJ Open Diabetes Research & Care, vol. 8, no. 2, 2020.